Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: FUDR
Floxuridine, also known as FdUrd, is a fluorinated pyrimidine nucleoside analog used in the treatment of advanced gastrointestinal adenocarcinoma, particularly colorectal cancer metastatic to the liver. It acts as an antimetabolite, inhibiting DNA synthesis and thereby interfering with cancer cell growth and proliferation. It is administered primarily via hepatic arterial infusion to target liver metastases directly.
For the treatment of advanced gastrointestinal adenocarcinoma metastatic to the liver.
Severe bone marrow suppression, including fatal myelosuppression, can occur. Administer via hepatic artery only. Close monitoring of hematologic parameters is essential.
Outcome:
Increased risk of myelosuppression
Mechanism:
Synergistic inhibition of DNA synthesis
Outcome:
Potentially increased floxuridine levels
Mechanism:
May affect hepatic metabolism
Outcome:
Potentially reduced absorption of floxuridine
Mechanism:
Changes in gastric pH
Most likely new formulation: Sustained-release hepatic arterial implant (Year: 2028, 60% confidence)
Based on the current clinical trial landscape and FDA approval trends, there is a 20% likelihood of an expanded indication for floxuridine in other solid tumors within the next 5 years.
Antineoplastic, Antimetabolite, Pyrimidine Analog
Pyrimidine nucleoside analog